Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of cancer using a CD123 chimeric antigen receptor

Treatment of cancer using a CD123 chimeric antigen receptor

US Patent 9815901 · Granted Nov 14, 2017

Estimated economic value: $8,342,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-TCR antibody molecules and uses thereof2025
CLDN18.2-targeting antibody, bispecific antibody and use thereof2025
Multispecific antibody molecules comprising lambda and kappa light chains2025
Matte ceramic tile and preparation method thereof2025
Chimeric antigen receptors and uses thereof2025
Antibody molecules that bind to NKP30 and uses thereof2025
Multifunctional molecules that bind to T cell related cancer cells and uses ther2025
Anti-TCR antibody molecules and uses thereof2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric a2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric a2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric a2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric a2025